Quickly uncover the breadth and depth of the editorial offerings found only in MedTech Strategist and Market Pathways – the medtech industry’s leading sources of global business, regulatory, and reimbursement analysis and intelligence on an all-in-one, digital platform. Think Strategically. Subscribe Today
Companies need to be mindful of the challenges FDA device reviewers are facing in the wake of staff cuts and ongoing instability. In this edition of Consultants Corner, former center reviewers offer advice on how companies currently pursuing premarket authorization should approach a beleaguered FDA.
With the acquisition from Stryker Spine, a $707 million commercial powerhouse at one end of the spectrum, and a small-molecule drug in Phase III clinical trials for degenerative disc disease at the other end, the Viscogliosis are making good on their vision of offering a continuum of integrated technologies for treating chronic back pain.
Abbott’s Aveir Conduction System Pacing leadless pacemaker system is in early feasibility trials. Excerpted from our recent feature article "Keeping the Beat".